<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T0002" orientation="portrait" position="float">
 <label>Table 2</label>
 <caption>
  <p>Grouping of antiretroviral drugs for design of regimens for treatment of HIV</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th rowspan="1" colspan="1">Group</th>
    <th rowspan="1" colspan="1">Antiretroviral drugs</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td rowspan="1" colspan="1">Nucleoside reverse-transcriptase inhibitors</td>
    <td rowspan="1" colspan="1">Zidovudine (Azt/Zdv); stavudine (d4T); lamivudine (3TC); abacavir (Abc); didanosine (ddl); zalcitabine (ddC); emtricitabine (FTC)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Nucleotide reverse-transcriptase inhibitors</td>
    <td rowspan="1" colspan="1">Tenofovir (TDF)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Non–nucleoside reverse-transcriptase inhibitors</td>
    <td rowspan="1" colspan="1">Nevirapine (Nvp); efavirenz (Efv); delavirdine (Dlv); rilpivirine (Rpv); eltravirine (Etv)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Protease inhibitors</td>
    <td rowspan="1" colspan="1">Saquinavir (Sqv); ritonavir (Rtv); nelfinavir (Nfv); amprenavir (Apv); indinavir (Inv); lopinavir (Lpv); fosamprenavir (Fpv); atazanavir (Atv); tipranavir (Tpv); darunavir (Drv)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Integrase strand–transferase inhibitors</td>
    <td rowspan="1" colspan="1">Raltegravir (Rgv); elvitegravir (Evg); dolutegravir (Dtg)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">Fusion inhibitors</td>
    <td rowspan="1" colspan="1">Enfuviritide (T20)</td>
   </tr>
   <tr>
    <td rowspan="1" colspan="1">CCR5 entry inhibitor</td>
    <td rowspan="1" colspan="1">Maraviroc</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
